Recent Updates — DBVT

DBV Technologies S.A. submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration for VIASKIN Peanut Patch, an epicutaneous immunotherapy treatment for peanut allergy in children aged 4 through 7 years. The submission is supported by positive results from the VITESSE Phase 3 clinical trial, which enrolled 654 children across 86 sites globally. DBV has requested Priority Review and previously received Breakthrough Therapy Designation for the product. This regulatory milestone marks a significant step toward commercialization for the late-stage biopharmaceutical company.

DBV Technologies S.A. issued a press release regarding its BLA submission update for the VIASKIN® Peanut Patch for children aged 4 through 7 years. The company is working collaboratively with the FDA to optimize the review process in preparation for filing. DBV Technologies S.A. is a biotechnology company focused on developing medical treatments for peanut allergies.

DBV Technologies S.A. approved its 2026 Performance Share Unit Plan and granted 4,060,000 performance share units (PSUs) to CEO Daniel Tassé. The award is contingent upon FDA approval of Viaskin Peanut biologics license applications, with 2,900,000 PSUs vesting upon the first approval and 1,160,000 PSUs vesting upon a second approval.